PubMed

Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells.

Liu W, He L, Ramírez J, Ratain MJ.

Clin Cancer Res. 2009 Dec 8. [Epub ahead of print]PMID: 19996219 [PubMed - as supplied by publisher]Related articles

COMPARISON OF THE DRUG-DRUG INTERACTIONS POTENTIAL OF ERLOTINIB AND GEFITINIB VIA INHIBITION OF UDP-GLUCURONOSYLTRANSFERASES.

Liu Y, Ramirez J, House L, Ratain MJ.

Drug Metab Dispos. 2009 Oct 22. [Epub ahead of print]PMID: 19850672 [PubMed - as supplied by publisher]Related articles

Other Paradigms: Better Treatments Are Identified by Better Trials: The Value of Randomized Phase II Studies.

Sharma MR, Maitland ML, Ratain MJ.

Cancer J. 2009 Sep-Oct;15(5):426-30.PMID: 19826363 [PubMed - in process]Related articles

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.

Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, Undevia SD, Stadler WM, Elliott WJ, Ratain MJ.

Clin Cancer Res. 2009 Oct 1;15(19):6250-7. Epub 2009 Sep 22.PMID: 19773379 [PubMed - in process]Related articles

A survey of the population genetic variation in the human kinome.

Zhang W, Catenacci DV, Duan S, Ratain MJ.

J Hum Genet. 2009 Aug;54(8):488-92. Epub 2009 Jul 31.PMID: 19644514 [PubMed - in process]Related articles

Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.

Hoskins JM, Rosner GL, Ratain MJ, McLeod HL, Innocenti F.

Pharmacogenomics. 2009 Jul;10(7):1139-46.PMID: 19604089 [PubMed - in process]Related articles

R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.

Yong WP, Kim TW, Undevia SD, Innocenti F, Ratain MJ.

Eur J Cancer. 2009 Jul;45(11):1904-8. Epub 2009 May 21.PMID: 19464879 [PubMed - indexed for MEDLINE]Related articles

Exploring the relationship between polymorphic (TG/CA)n repeats in intron 1 regions and gene expression.

Zhang W, He L, Liu W, Sun C, Ratain MJ.

Hum Genomics. 2009 Apr;3(3):236-45.PMID: 19403458 [PubMed - indexed for MEDLINE]Related articles

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.

Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ.

J Clin Oncol. 2009 Jun 1;27(16):2604-14. Epub 2009 Apr 6.PMID: 19349540 [PubMed - indexed for MEDLINE]Related articles

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.

Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, Lewis LD, Fakih MG, Edelman MJ, Millard F, Frank RC, Hohl RJ, Ratain MJ.

J Clin Oncol. 2009 Apr 10;27(11):1800-5. Epub 2009 Mar 2.PMID: 19255312 [PubMed - indexed for MEDLINE]Related articles

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.

Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL, Bedrosian C, Ratain MJ.

Clin Cancer Res. 2009 Feb 15;15(4):1428-34.PMID: 19228743 [PubMed - indexed for MEDLINE]Related articles

Biomarkers in early cancer drug development: limited utility.

Glassman RH, Ratain MJ.

Clin Pharmacol Ther. 2009 Feb;85(2):134-5. Review.PMID: 19151638 [PubMed - indexed for MEDLINE]Related articles

Pharmacogenetics and pharmacogenomics of anticancer agents.

Huang RS, Ratain MJ.

CA Cancer J Clin. 2009 Jan-Feb;59(1):42-55. Review.PMID: 19147868 [PubMed - indexed for MEDLINE]Related articlesFree article

Genome-wide identification of genetic determinants for the cytotoxicity of perifosine.

Zhang W, Liu W, Poradosu E, Ratain MJ.

Hum Genomics. 2008 Sep;3(1):53-70.PMID: 19129090 [PubMed - indexed for MEDLINE]Related articles

Optimising the design of phase II oncology trials: the importance of randomisation.

Ratain MJ, Sargent DJ.

Eur J Cancer. 2009 Jan;45(2):275-80. Epub 2008 Dec 6.PMID: 19059773 [PubMed - indexed for MEDLINE]Related articles

Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.

Perera MA, Thirumaran RK, Cox NJ, Hanauer S, Das S, Brimer-Cline C, Lamba V, Schuetz EG, Ratain MJ, Di Rienzo A.

Pharmacogenomics J. 2009 Feb;9(1):49-60. Epub 2008 Sep 30.PMID: 18825162 [PubMed - indexed for MEDLINE]Related articlesFree article

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.

Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WM.

J Clin Oncol. 2008 Oct 1;26(28):4572-8.PMID: 18824708 [PubMed - indexed for MEDLINE]Related articlesFree article

Nonprofit biomedical companies.

Conti RM, Meltzer DO, Ratain MJ.

Clin Pharmacol Ther. 2008 Aug;84(2):194-7.PMID: 18679181 [PubMed - indexed for MEDLINE]Related articles

The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.

Innocenti F, Mirkov S, Nagasubramanian R, Ramírez J, Liu W, Bleibel WK, Shukla SJ, Hennessy K, Rosner GL, Cook E Jr, Eileen Dolan M, Ratain MJ.

Cancer Chemother Pharmacol. 2009 Apr;63(5):881-7. Epub 2008 Aug 2.PMID: 18677484 [PubMed - indexed for MEDLINE]Related articles

A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.

Undevia SD, Innocenti F, Ramirez J, House L, Desai AA, Skoog LA, Singh DA, Karrison T, Kindler HL, Ratain MJ.

Eur J Cancer. 2008 Aug;44(12):1684-92. Epub 2008 Jul 21.PMID: 18650079 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.

Bartlett NL, Johnson JL, Wagner-Johnston N, Ratain MJ, Peterson BA; Cancer and Leukemia Group B.

Cancer Chemother Pharmacol. 2009 Apr;63(5):793-8. Epub 2008 Jul 23.PMID: 18648813 [PubMed - indexed for MEDLINE]Related articles

Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene.

Innocenti F, Liu W, Fackenthal D, Ramírez J, Chen P, Ye X, Wu X, Zhang W, Mirkov S, Das S, Cook E Jr, Ratain MJ.

Pharmacogenet Genomics. 2008 Aug;18(8):683-97.PMID: 18622261 [PubMed - indexed for MEDLINE]Related articlesFree article

Creating and evaluating genetic tests predictive of drug response.

Weiss ST, McLeod HL, Flockhart DA, Dolan ME, Benowitz NL, Johnson JA, Ratain MJ, Giacomini KM.

Nat Rev Drug Discov. 2008 Jul;7(7):568-74. Epub 2008 Jun 20.PMID: 18587383 [PubMed - indexed for MEDLINE]Related articlesFree article

Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?

Perera MA, Innocenti F, Ratain MJ.

Pharmacotherapy. 2008 Jun;28(6):755-68. Review.PMID: 18503403 [PubMed - indexed for MEDLINE]Related articles

A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.

Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJ.

Invest New Drugs. 2008 Aug;26(4):331-8. Epub 2008 Apr 19.PMID: 18425419 [PubMed - indexed for MEDLINE]Related articles

Pharmacogenetic pathway analysis of irinotecan.

Rosner GL, Panetta JC, Innocenti F, Ratain MJ.

Clin Pharmacol Ther. 2008 Sep;84(3):393-402. Epub 2008 Apr 16.PMID: 18418374 [PubMed - indexed for MEDLINE]Related articlesFree article

The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics.

Zhang W, Ratain MJ, Dolan ME.

Bioinform Biol Insights. 2008;2:15-23.PMID: 18392109 [PubMed]Related articlesFree article

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.

Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ.

J Clin Oncol. 2008 Mar 1;26(7):1119-27.PMID: 18309947 [PubMed - indexed for MEDLINE]Related articles

Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.

Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Desai AA, Singleton PA, Sammani S, Sam L, Liu Y, Husain AN, Lang RM, Ratain MJ, Lussier YA, Garcia JG.

Physiol Genomics. 2008 Apr 22;33(2):278-91. Epub 2008 Feb 26.PMID: 18303084 [PubMed - indexed for MEDLINE]Related articlesFree article

Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.

Daugherty CK, Ratain MJ, Emanuel EJ, Farrell AT, Schilsky RL.

J Clin Oncol. 2008 Mar 10;26(8):1371-8. Epub 2008 Jan 28. Review.PMID: 18227527 [PubMed - indexed for MEDLINE]Related articles

Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.

Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, Karrison TG, Ratain MJ, Stock W.

Invest New Drugs. 2008 Jun;26(3):233-9. Epub 2008 Jan 24.PMID: 18217206 [PubMed - indexed for MEDLINE]Related articles

Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.

Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, Huff LM, Innocenti F, Das S, Cook EH Jr, Cox NJ, Bates SE, Ratain MJ.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6788-95.PMID: 18006781 [PubMed - indexed for MEDLINE]Related articlesFree article

Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?

Ratain MJ, Glassman RH.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6545-8. No abstract available. PMID: 18006752 [PubMed - indexed for MEDLINE]Related articlesFree article

The investigational drug steering committee.

Ratain MJ.

Clin Adv Hematol Oncol. 2007 Oct;5(10):779-80. No abstract available. PMID: 17998895 [PubMed - indexed for MEDLINE]Related articles

Recommended changes to oncology clinical trial design: revolution or evolution?

Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, Stadler WM, Berry DA, Peck CC.

Eur J Cancer. 2008 Jan;44(1):8-11. Epub 2007 Nov 5. No abstract available. PMID: 17981025 [PubMed - indexed for MEDLINE]Related articlesFree article

Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?".

Chabner BA, Ratain MJ.

Clin Cancer Res. 2007 Nov 1;13(21):6540. No abstract available. PMID: 17975169 [PubMed - indexed for MEDLINE]Related articlesFree article

Interpreting P values in pharmacogenetic studies: a call for process and perspective.

Maitland ML, Ratain MJ, Cox NJ.

J Clin Oncol. 2007 Oct 10;25(29):4513-5. No abstract available. PMID: 17925544 [PubMed - indexed for MEDLINE]Related articles

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.

Karrison TG, Maitland ML, Stadler WM, Ratain MJ.

J Natl Cancer Inst. 2007 Oct 3;99(19):1455-61. Epub 2007 Sep 25. Erratum in: J Natl Cancer Inst. 2007 Dec 5;99(23):1819. PMID: 17895472 [PubMed - indexed for MEDLINE]Related articlesFree article

Lack of association between common polymorphisms in UGT1A9 and gene expression and activity.

Ramírez J, Liu W, Mirkov S, Desai AA, Chen P, Das S, Innocenti F, Ratain MJ.

Drug Metab Dispos. 2007 Dec;35(12):2149-53. Epub 2007 Aug 30.PMID: 17761781 [PubMed - indexed for MEDLINE]Related articlesFree article

Rapamycin: something old, something new, sometimes borrowed and now renewed.

Hartford CM, Ratain MJ.

Clin Pharmacol Ther. 2007 Oct;82(4):381-8. Epub 2007 Aug 29. Review.PMID: 17728765 [PubMed - indexed for MEDLINE]Related articles

Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials.

Gray SW, Hlubocky FJ, Ratain MJ, Daugherty CK.

J Clin Oncol. 2007 Aug 10;25(23):3488-94.PMID: 17687154 [PubMed - indexed for MEDLINE]Related articles

The value meal: how to save $1,700 per month or more on lapatinib.

Ratain MJ, Cohen EE.

J Clin Oncol. 2007 Aug 10;25(23):3397-8. Epub 2007 Jul 16. No abstract available. PMID: 17635950 [PubMed - indexed for MEDLINE]Related articles

Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.

Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM, Ratain MJ.

J Clin Oncol. 2007 Jul 20;25(21):3055-60.PMID: 17634483 [PubMed - indexed for MEDLINE]Related articles

UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers.

Yoder Graber AL, Ramírez J, Innocenti F, Ratain MJ.

Pharmacogenet Genomics. 2007 Aug;17(8):619-27.PMID: 17622938 [PubMed - indexed for MEDLINE]Related articles

A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.

Lewis LD, Miller AA, Rosner GL, Dowell JE, Valdivieso M, Relling MV, Egorin MJ, Bies RR, Hollis DR, Levine EG, Otterson GA, Millard F, Ratain MJ; Cancer and Leukemia Group B.

Clin Cancer Res. 2007 Jun 1;13(11):3302-11.PMID: 17545536 [PubMed - indexed for MEDLINE]Related articlesFree article

Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms.

Zhang W, Liu W, Innocenti F, Ratain MJ.

PLoS One. 2007 Apr 25;2(4):e396.PMID: 17460763 [PubMed]Related articlesFree article

Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver.

Ramírez J, Mirkov S, Zhang W, Chen P, Das S, Liu W, Ratain MJ, Innocenti F.

Pharmacogenomics J. 2008 Apr;8(2):152-61. Epub 2007 Apr 17.PMID: 17440429 [PubMed - indexed for MEDLINE]Related articles

Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties.

Michaelis LC, Ratain MJ.

Clin Cancer Res. 2007 Apr 15;13(8):2400-5.PMID: 17438099 [PubMed - indexed for MEDLINE]Related articlesFree article

The pharmacogenetics research network: from SNP discovery to clinical drug response.

Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I; Pharmacogenetics Research Network.

Clin Pharmacol Ther. 2007 Mar;81(3):328-45. Review.PMID: 17339863 [PubMed - indexed for MEDLINE]Related articles

Personalized medicine: building the GPS to take us there.

Ratain MJ.

Clin Pharmacol Ther. 2007 Mar;81(3):321-2. No abstract available. PMID: 17339859 [PubMed - indexed for MEDLINE]Related articles